60940-34-3
60940-34-3 結(jié)構(gòu)式
基本信息
依布硒啉
2-苯基苯并異硒唑3-酮
依布硒, 依布硒啉
2-phenyl-benzo[d]isoselenazol-3-one
EBSELEN
PZ51
2-phenyl-2-benzisoselenazol-3(2h)-one
EBSELEN (PZ51, 2-PHENYL-1,2-BENZISOSELEN AZOL-3(2H)-ONE)
EBSELEN 99%
2-phenyl-1,2-benzisoselenazol-
2-Phenyl-1,2-benzoselenazol-3-one
Harmokisane
2-Phenyl-1-selena-2-azaindan-3-one
DR-3305
RP-60931
物理化學性質(zhì)
安全數(shù)據(jù)
常見問題列表
| Target | Value |
|
HIV-1
(Cell-free assay) | 46.1 nM |
Ebselen (SPI-1005; 0.4-100 μM; 20-24 hours) shows strong antiviral effects at a concentration of 10 μM treatment in COVID-19 virus infected Vero cells. Ebsele covalently binds to C145 of the catalytic dyad in COVID-19 virus Mpro.
Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process.
Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. Ebselen inhibits inositol monophosphatase (IMPase).
Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic, renal cancer cell lines.
RT-PCR
| Cell Line: | COVID-19 virus infected Vero cells |
| Concentration: | 0.4, 1.2, 3.7, 11.1, 33.3, 100 μM |
| Incubation Time: | 20-24 hours |
| Result: | Showed strong antiviral effects at a concentration of 10 μM treatment. |
Ebselen (5, 10 mg/kg; IP) decreases 5-HT 2 agonist-induced head twitches in a dose-dependent manner.
| Animal Model: | 20-25 g 10-12 week old male C57Bl6 mice |
| Dosage: | 5, 10 mg/kg |
| Administration: | IP |
| Result: | Decreased 5-HT 2 agonist-induced head twitches in a dose-dependent manner. |
知名試劑公司產(chǎn)品信息
Ebselen, 99%(60940-34-3)